Snipr Biome CEO delighted over FDA fast-track status
CEO Christian Grøndahl now looks forward to more communication with the FDA, which could allow for Snipr Biome’s drug candidate to reach the market faster than before.
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen
Co-Founder and CEO at Snipr Biome Christian Grøndahl is very excited about the fact that the US Food and Drug Administration (FDA) recently awarded its special fast-track designation to the biotech company’s candidate, SNIPR001.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA fast-tracks Snipr Biome's primary candidate
For subscribers
Snipr Biome chose clinical debut in CRISPR-ready USA
For subscribers
Snipr Biome to send first candidate to clinic
For subscribers
